BIND News
Archived Headlines
- Cancer biotech BIND Therapeutics sets terms for $71 million IPO 09/05/13
- US IPO Recap: Regado slashes valuation, three deals added to IPO pipeline 08/26/13
- US IPO Recap: 2013 breaks past 2012's IPO totals in pricings and filings 08/19/13
- Cancer biotech BIND Therapeutics files for a $81 million IPO 08/12/13
US IPO Recap: Blazing debuts for software trio FireEye, Rocket Fuel and Benefitfocus
Rocket Fuel and FireEye had first-day returns (93% and 80%, respectively) to match their incendiary names last week, but neither could touch Benefitfocus's 102% first-day pop, just the tenth first-day double since 2000. The three represented the most 80%+...read more
BIND Therapeutics prices IPO at $15, within the range
BIND Therapeutics, a biotech developing targeting mechanisms to enhance existing therapeutics, raised $71 million by offering 4.7 million shares at $15, within the range of $14 to $16. BIND Therapeutics plans to list on the NASDAQ under the symbol BIND. BIND...read more
12 US IPOs planned for the week of Sep 16
The following IPOs are expected to price this week: Acceleron Pharma (XLRN), a clinical stage biotech developing protein therapeutics for cancer and rare diseases, plans...read more
US IPO Recap: Benefitfocus, six others set terms as calendar rebuilds
Joined by fast-growing SaaS company Benefitfocus (BNFT), four biotechs led the way in rebuilding the US IPO calendar last week. Matching the total for all of August, seven companies...read more